Modification of the salivary secretion assay in F508del mice — The murine equivalent of the human sweat test Karoline Droebner, Peter Sandner Journal.

Slides:

Advertisements

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Advertisements

Azithromycin fails to reduce increased expression of neutrophil-related cytokines in primary-cultured epithelial cells from cystic fibrosis mice Ximena.

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function Fredrick Van Goor, Haihui Yu, Bill.

Cystic fibrosis: A new mutation in the Lebanese population

Effect of VX-770 (Ivacaftor) and OAG on Ca2+ influx and CFTR activity in G551D and F508del-CFTR expressing cells Laura Vachel, Caroline Norez, Frédéric.

Heleen Van Acker, Elisabeth Van Snick, Hans J. Nelis, Tom Coenye

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis P. Gonçalves.

Katarine Egressy, Michaelene Jansen, Keith C. Meyer

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Nadav Traeger, Qiuhu Shi, Allen J. Dozor Journal of Cystic Fibrosis

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Cirrhosis and other liver disease in cystic fibrosis

The ease of breathing test tracks clinical changes in cystic fibrosis

Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking Graeme W. Carlile, Renaud Robert, Julie Goepp, Elizabeth Matthes,

Bronchial epithelial cell lines and primary nasal epithelial cells from cystic fibrosis respond differently to cigarette smoke exposure Mark Thomas Shaw.

Expression of the inflammatory regulator A20 correlates with lung function in patients with cystic fibrosis Catriona Kelly, Mark T. Williams, J. Stuart.

Controlled clinical trials in cystic fibrosis — are we doing better?

Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week- days during school term-time Rosemary Ball, Kevin W. Southern, Pamela.

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients J.L. Fothergill,

Rebecca J. Darrah, Ilya R. Bederman, Anna L. Mitchell, Craig A

Vitamin A and lung function in CF

Prenatal diagnosis for CF using High Resolution Melting Analysis and simultaneous haplotype analysis through QF-PCR Myrto Poulou, Aspasia Destouni, Georgia.

Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis Donna Drury, Vijay Laxmi Grey, Guylaine Ferland, Caren Gundberg,

The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation Verena I. Seliger, David Rodman, Fredrick Van.

A.H. Gifford Journal of Cystic Fibrosis

M. Wouthuyzen-Bakker, F.A.J.A. Bodewes, H.J. Verkade

Shaoyan Zhang, Neel K. Ranganath, Daniel Skinner, David M

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Feasibility of parental collected nasal swabs for virus detection in young children with cystic fibrosis C.L. Gangell, C. Shackleton, S. Poreddy, J.

Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J

Early pulmonary disease manifestations in cystic fibrosis mice

Cytokine gene polymorphisms and severity of CF lung disease

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Nasal polyposis in lung transplant recipients with cystic fibrosis

Stimulation of salivary secretion in vivo by CFTR potentiators in Cftr+/+ and Cftr−/− mice Sabrina Noël, Pierre-Olivier Strale, Luc Dannhoffer, Martina.

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa Karen O. McKay, Peter J. Cooper, Peter P. van.

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Disease disclosure in individuals with cystic fibrosis: Association with psychosocial and health outcomes Adrienne P. Borschuk, Robin S. Everhart, Michelle.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

A new method of sweat testing: the CF Quantum®sweat test

Denise S. K. Brookes, Julie N. Briody, Craig F. Munns, Peter S. W

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

V. Terlizzi, A. Tosco, R. Tomaiuolo, A. Sepe, N. Amato, A. Casale, C

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Beta-lactam allergy in adults with cystic fibrosis

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Anne K. Swisher, Kathryn Moffett, Linda Baer

Absence of a gender gap in survival

Cystic fibrosis and pregnancy in the modern era: A case control study

Uta Griesenbach, A. Christopher Boyd Journal of Cystic Fibrosis

Presentation transcript:

Modification of the salivary secretion assay in F508del mice — The murine equivalent of the human sweat test Karoline Droebner, Peter Sandner Journal of Cystic Fibrosis Volume 12, Issue 6, Pages 630-637 (December 2013) DOI: 10.1016/j.jcf.2013.05.001 Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Average maximum saliva flow rates from homozygous (CF, white bars), heterozygous (Hz, grey bars) and wild-type (WT, black bars) CFTRtm1Unc, CFTRtm1Kth and CFTRtm1Eur mice. (A) Basal salivary flow rates. (B) Acetylcholine-stimulated salivary flow rates. (C) Acetylcholine-stimulated salivary flow rates in the presence of atropine. (D) Isoprenaline-stimulated salivary flow rates in the presence of atropine. Data are expressed as mean±SEM. n=20/group. Significant differences were determined by Tukey's multiple comparison test (*/**/***=significant versus WT with p<0.05/0.01/0.001; #/##/###=significant versus heterozygous with p<0.05/0.01/0.001; °/°°/°°°=significant versus CFTRtm1Unc with p<0.05/0.01/0.001; ^/^^/^^^=significant versus CFTRtm1Kth with p<0.05/0.01/0.001). Journal of Cystic Fibrosis 2013 12, 630-637DOI: (10.1016/j.jcf.2013.05.001) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Salivary chloride content in Isoprenaline-stimulated saliva from wild-type (WT; black bars), heterozygous (Hz; grey bars) and homozygous (CF; white bars) CFTRtm1Eur mice. Data are expressed as mean±SEM. n=5 pools with a total of 30 mice. Significant differences were determined by Tukey's multiple comparison test (*/**/***=significant with p<0.05/0.01/0.001). Journal of Cystic Fibrosis 2013 12, 630-637DOI: (10.1016/j.jcf.2013.05.001) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Salivary chloride content in Pilocarpine-stimulated saliva from wild-type (WT; black bar), heterozygous (Hz; grey bars) and homozygous (CF; white bars) CFTRtm1Unc, CFTRtm1Kth and CFTRtm1Eur mice. Data are expressed as mean±SEM. n=8/group. Significant differences were determined by Tukey's multiple comparison test (*/**/***=significant with p<0.05/0.01/0.001). Journal of Cystic Fibrosis 2013 12, 630-637DOI: (10.1016/j.jcf.2013.05.001) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions